In 2008 was created Kunlun, which is appeared as VC. The venture was found in Asia in China. Kunlun appeared to be a CVC structure as part of the corporation. The main office of represented VC is situated in the Beijing.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Kunlun, startups are often financed by Source Code Capital, SAIF Partners, ZhenFund. The meaningful sponsors for the fund in investment in the same round are Source Code Capital, ZhenFund, Sequoia Capital China. In the next rounds fund is usually obtained by Source Code Capital, Walmart, Sequoia Capital China.
The top activity for fund was in 2015. Despite it in 2019 the fund had an activity. The real fund results show that this VC is 47 percentage points more often commits exit comparing to other companies. The higher amount of exits for fund were in 2018. The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in 2-6 deals per year. The average startup value when the investment from Kunlun is 100-500 millions dollars. This Kunlun works on 16 percentage points less the average amount of lead investments comparing to the other organizations.
The fund was created by Yahui Zhou.
Among the most popular portfolio startups of the fund, we may highlight Qudian, Club Factory, Feidee. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Automotive, Higher Education. The fund has specific favorite in a number of founders of portfolio startups.
Funds with similar focus
|Chishan Group||China, Japan, Kagoshima Prefecture|
|Eaton Gate Capital Partners||Castel, Guernsey, Guernsey|
|Gongye Yuanqu Investment||China, Jiaxing, Zhejiang|
|Health Resources and Services Administration||Maryland, Rockville, United States|
|Huda Associates||England, London, United Kingdom|
|Kline Hawkes & Co||California, Los Angeles, United States|
|Liftaeknisjodurinn HF||Gullbringusysla, Iceland, Reykjavík|
|New General Market Ventures||New City, New York, United States|
|Rainbow Capital||Franklin Lakes, New Jersey, United States|
|Sage Venture Capital||-|
|Science Creates Ventures||-|
|Senshu Ikeda Capital||Japan, Osaka, Osaka Prefecture|
|Sequel Fund||Kentucky, Louisville, United States|
|ServiceMaster||Memphis, Tennessee, United States|
|Shigagin Lease Capital||Japan, Otsu, Shiga Prefecture|
|WaterStart Capital||Atlanta, Georgia, United States|
|Welkin Capital Management||China, Hong Kong, Hong Kong Island|
|WM Motor||China, Shanghai|
|$83M||21 Apr 2022||San Francisco, California, United States|
|$40M||14 Mar 2022||Shanghai, Shanghai, China|
|$96M||27 Dec 2021||Jakarta, Jakarta Raya, Indonesia|
|$5M||28 Sep 2021||Pasadena, California, United States|
|20 Jul 2021||Hangzhou, Zhejiang, China|
|$100M||02 Mar 2021||Xiangzhou District, Guangdong Province, China|
|29 Dec 2020||-|
|$270M||17 Nov 2020||California, United States|
|$67M||13 Oct 2020||Dongcheng District, Beijing, China|
– Biotheus announced the completion of a fourth round of financing, co-led by General Atlantic and IDG Capital.
– New investors include Kunlun Capital, CPE, and Cowin Capital.
– Biotheus is a clinical development stage company with the mission of treating cancer and autoimmune diseases through next-generation therapeutics.
– This is supported by the company’s product pipeline, which consists of over 10 novel monoclonal and multispecific antibodies.
– Biotheus currently has two bispecific antibodies in phase I clinical development for cancer treatment, and a third IND application was submitted at the end of 2020.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.